Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...

As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...

A recent study from ixlayer indicates patients are looking for pharma companies to do more to improve upon their current DTC offerings.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Following the FDA’s decision to end the semaglutide shortage, Hims transitioned away from compounded GLP-1 prescriptions and began offering branded alternatives through a new partnership with Novo ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...